Hong Kong-listed TATA Health International Holdings Limited (Stock code: 1255) has announced that it has fulfilled all resumption guidance issued by the Stock Exchange of Hong Kong. Trading in its shares, which had been suspended since 2 April 2024, is set to resume on 1 December 2025.
TATA Health clarified that it has published all outstanding financial reports, including annual and interim results from 2023 to 2025, and addressed related audit concerns. The company further indicated that any remaining audit modifications are expected to be fully removed by fiscal year 2027 without ongoing effects on its future consolidated statements. According to the announcement, management has also confirmed sufficient working capital for at least the next 18 months.
A key part of TATA Health’s resumption plan involved re-focusing on its core footwear business and divesting certain loss-making healthcare, financial services, and online medical services segments. The company now operates two principal footwear models—a long-standing distributorship arrangement and a retail-as-a-service framework with an external partner—to streamline costs and improve operational efficiency. Management projects continued revenue growth, citing a potential memorandum of understanding with a global French fashion brand to broaden the company’s product portfolio and geographic footprint.
In addition to commercial restructuring, TATA Health re-established its board and committee composition to meet Listing Rule requirements. Several directors and executives were appointed or re-designated, ensuring compliance with governance standards regarding independent directors and committee memberships. An independent consultancy also completed an internal control review, leading to further enhancements in corporate governance and risk management.
Having satisfied the Stock Exchange’s conditions and issued multiple updates regarding board changes, financial audits, and operational developments, TATA Health has confirmed it will resume trading, with management underscoring that current business and governance structures meet the relevant listing obligations.